Accelerating development of genetic therapies for muscular dystrophies
The aim of MAGIC is to accelerate the development of gene therapies and genome editing strategies for muscular dystrophies by creating advanced humanized muscle models and innovative gene therapy approaches, ultimately improving the lives of individuals affected by these debilitating diseases.
Key Objectives
- Creating accurate humanized muscle models.
- Developing precise gene therapies and genome editing strategies.
- Engineering disease-specific muscle-on-chip devices.
- Assessing safety and efficacy of novel gene therapies.
- Exploring gene editing strategies for neuromuscular disorders.
- Facilitating translation and exploitation of project outputs.
- Ensuring patient perspectives remain central to the research.
See how MAGIC is working to reach these key objectives
Latest News
Rare Disease Day with the MAGIC team
Rare Disease Day is observed every year on 28 February. It was established and coordinated by EURORDIS in partnership with over 70 national alliance patient organisations to spotlight the 300...
MAGIC Experts Share Knowledge Through Interactive Workshops
As part of our annual General Assembly meeting in Lisbon (27–30 October 2025), MAGIC hosted a series of workshops designed to share expertise with the wider research community. The first workshop...
MAGIC GA Meeting 2025 Lisbon
MAGIC partners gather in Lisbon for annual General Assembly The MAGIC consortium held its annual General Assembly from 28–30 October in Lisbon, hosted by our partners at the Gulbenkian Institute for...